Get the Weekly Intelligence Brief — top committee picks every Sunday.

OMDA vs PEN

Omada Health vs Penumbra, Inc. — AI-powered side-by-side comparison
OMDA
Omada Health
59
Buy
VS
PEN
Penumbra, Inc.
67
Buy
MetricOMDAPEN
AI Score 59 67
Price $24.00 $326.07
P/E Ratio 353.61× 79.78×
ROE -5.6% 12.4%
Revenue Growth YoY
Gross Margin 68.2% 67.8%
Debt / Equity 0.00× 0.14×
Dividend Yield 0.0% 0.0%
RSI (14) 66.6 79.6
Beta 1.7204 0.701
Expected Upside +6.3%

AI Committee View

Current Innellis committee reasoning for OMDA versus PEN.
PEN leads by 8 points.

PEN scores 67/100 (Buy) versus OMDA at 59/100 (Buy).

OMDA Committee View
50% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 35.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Bollinger bandwidth of 35.5% signals elevated volatility — Risk
PEN Committee View
80% agreement
5 analysts

The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • 2 consecutive earnings misses -- execution concerns — Growth
  • RSI at 80 is in overbought territory — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
OMDA Full Analysis PEN Full Analysis